Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis
Open accessAbstract
Amphotericin B (AMB) remains the principal therapeutic choice for deep mycoses. However, its application is limited by toxicity and a route of administration requiring slow intravenous injection. An oral formulation of this drug is desirable to treat acute infections and provide prophylactic therapy for high-risk patients. Cochleates are a novel lipid-based delivery system that have the potential for oral administration of hydrophobic drugs. They are stable phospholipid-cation crystalline structures consisting of a spiral lipid bilayer sheet with no internal aqueous space. Cochleates containing AMB (CAMB) inhibit the growth of Candida albicans, and the in vivo therapeutic efficacy of CAMB administered orally was evaluated in a mouse model of systemic candidiasis. The results indicate that 100% of the mice treated at all CAMB doses, including a low dosage of 0.5 mg/kg of body weight/day, survived the experimental period (16 days). In contrast, 100% mortality was observed with untreated mice by day 12. The fungal tissue burden in kidneys and lungs was assessed in parallel, and a dose-dependent reduction in C. albicans from the kidneys was observed, with a maximum 3.5-log reduction in total cell counts at 2.5 mg/kg/day. However, complete clearance of the organism from the lungs, resulting in more than a 4-log reduction, was observed at the same dose. These results were comparable to a deoxycholate AMB formulation administered intraperitoneally at 2 mg/kg/day (P < 0.05). Overall, these data demonstrate that cochleates are an effective oral delivery system for AMB in a model of systemic candidiasis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Orally administered MAT2203 prevented death in mice with invasive candidiasis.
“Orally administered MAT2203 prevented death”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [119]
Orally administered MAT2203 reduced tissue fungal burden in mice with invasive candidiasis.
“reduced tissue fungal burden in mice with invasive candidiasis [119,120]”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Apoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & HARMON, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8 · Cited by 2,118 · see citing works
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Beck‐Sagué, C. M., Jarvis, W. R., & System, N. N. I. S. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140 · see citing works
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,013 · see citing works
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758 · see citing works
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679 · see citing works
Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A. C., Bow, E. J., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 623 · see citing works
Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles
Papahadjopoulos, D., Vail, W. J., Jacobson, K., & Poste, G. H. (1975) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(75)90299-0 · Cited by 544 · see citing works
Amphotericin B: current understanding of mechanisms of action
Brajtburg, J., Powderly, W. G., Kobayashi, G. S., & Medoff, G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.2.183 · Cited by 503 · see citing works
Prospective Multicenter Surveillance Study of Funguria in Hospitalized Patients
Kauffman, C. A., Vazquez, J. A., Sobel, J. D., Gallis, H. A., McKinsey, D. S., Karchmer, A. W., Sugar, A. M., Sharkey, P. K., Wise, G. J., Mangi, R., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313583 · Cited by 483 · see citing works
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404 · see citing works
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Wong‐Beringer, A., Jacobs, R. A., & Guglielmo, B. J. (1998) · Clinical Infectious Diseases · doi:10.1086/514704 · Cited by 398 · see citing works
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00240-x · Cited by 332 · see citing works
Leenders, A. C. A. P., Daenen, S. M. G. J., Jansen, R. L. H., Hop, W. C. J., Löwenberg, B., Wijermans, P., Cornelissen, J. J., Herbrecht, R., van der Lelie, H., Hoogsteden, H. C., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00944.x · Cited by 317 · see citing works
Predictors of Adverse Outcome in Cancer Patients with Candidemia
Anaissie, E. J., Rex, J. H., Uzun, Ö., & Vartivarian, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00030-8 · Cited by 295 · see citing works
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Hollis, R. J., Messer, S. A., & Group, F. T. S. P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.1886-1889.1998 · Cited by 281 · see citing works
Adler‐Moore, J., & Proffitt, R. T. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150729 · Cited by 252 · see citing works
Sabra, R., & Branch, R. A. (1990) · Drug Safety · doi:10.2165/00002018-199005020-00003 · Cited by 229 · see citing works
Goodrich, J. M., Reed, E. C., Mori, M., Fisher, L. D., Skerrett, S. J., Dandliker, P. S., Klis, B. M. V. D., Counts, G. W., & Meyers, J. D. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.4.731 · Cited by 214 · see citing works
Sawaya, B. P., Briggs, J. P., & Schnermann, J. B. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v62154 · Cited by 203 · see citing works
Walsh, T. J., Yeldandi, V. V., McEvoy, M., Gonzalez, C. E., Chanock, S. J., Freifeld, A. G., Seibel, N., Whitcomb, P. O., Jarosinski, P. F., Boswell, G. W., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2391 · Cited by 189 · see citing works
Zarif, L., Graybill, J. R., Perlin, D., Najvar, L., Bocanegra, R., & Mannino, R. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1463-1469.2000 · Cited by 122 · see citing works
Amphotericin B: an introduction
Warnock, D. W. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.27 · Cited by 121 · see citing works
Nieto-Rodríguez, J. A., Kusne, S., Máñez, R., Irish, W. D., Linden, P., Magnone, M., Wing, E. J., Fung, J. J., & Starzl, T. E. (1996) · Annals of Surgery · doi:10.1097/00000658-199601000-00010 · Cited by 110 · see citing works
AmBisome targeting to fungal infections.
Adler‐Moore, J. (1994) · PubMed · Cited by 107 · see citing works
Collette, N., van der Auwera, P., Lopez, A. P., Heymans, C., & Meunier, F. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.3.362 · Cited by 102 · see citing works
Liposomal amphotericin B, AmBisome
Hay, R. J. (1994) · Journal of Infection · doi:10.1016/s0163-4453(94)95956-0 · Cited by 97 · see citing works
Treatment of Opportunistic Fungal Infections
Armstrong, D. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/16.1.1 · Cited by 96 · see citing works
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Walsh, T. J., Gonzalez, C., Lyman, C. A., Chanock, S. J., & Pizzo, P. A. (1996) · PubMed · Cited by 93 · see citing works
Adler‐Moore, J., Chiang, S.-M., Satorius, A., Guerra, D., McAndrews, B., McManus, E. J., & Proffitt, R. T. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.suppl_b.63 · Cited by 81 · see citing works
A comparative review of conventional and lipid formulations of amphotericin B
Robinson, R. F., & Nahata, M. C. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00220.x · Cited by 72 · see citing works
Wright, W. L., & Wenzel, R. P. (1997) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70363-9 · Cited by 70 · see citing works
Development of liposomal amphotericin B formulation
Gulati, M., Bajad, S. U., Singh, S., Ferdous, A. J., & Singh, M. S. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006844 · Cited by 69 · see citing works
Engel, R. R., Satzger, W., Günther, W., Kathmann, N., Bove, D., Gerke, S., Münch, U., & Hippius, H. (1992) · European Neuropsychopharmacology · doi:10.1016/0924-977x(92)90025-4 · Cited by 67 · see citing works
Liposomes: Realizing Their Promise
Bangham, A. D. (1992) · Hospital Practice · doi:10.1080/21548331.1992.11705537 · Cited by 66 · see citing works
Antibiotic-related nephrotoxicity.
Kaloyanides, G. J. (1994) · PubMed · Cited by 50 · see citing works
Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations.
Heinemann, V., Kähny, B., Debus, A., Wachholz, K., & Jehn, U. (1994) · PubMed · Cited by 38 · see citing works
Absorption of orally administered amphotericin B lozenges.
Ching, M., Raymond, K., Bury, R. W., Mashford, M., & Morgan, D. J. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb02152.x · Cited by 35 · see citing works
Groll, A. H., Müller, F. C., Piscitelli, S. C., & Walsh, T. J. (1998) · Klinische Pädiatrie · doi:10.1055/s-2008-1043890 · Cited by 33 · see citing works
Zarif, L., & Mannino, R. J. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46817-4_9 · Cited by 29 · see citing works
Brajtburg, J., Elberg, S., Kobayashi, G. S., & Bolard, J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.2.300 · Cited by 28 · see citing works
Gallis, H. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s145 · Cited by 28 · see citing works
Villardita, C., Grioli, S., & Salmeri, G. (1987) · Cited by 21 · see citing works
Safety of high-dose Amphotericin B lipid complex
Singhal, S., Hastings, J. G. M., & Mutimer, D. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701829 · Cited by 7 · see citing works
Flagged first, then by citations
1 of the 44 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- [26]Mannino R J, Gould-Fogerite S. Antigen cochleate formulations for oral and systemic vaccination in new generation vaccines. In: Levine M M, editor. New generation vaccines. New York, N.Y: Marcel Dekker; 1997. pp. 1–9. [Google Scholar]
- [27]National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, NCCLS document M27-A. Wayne, Pa: National Committee for Clinical Laboratory Standards; 1997. [Google Scholar]
- [44]Zarif L, Mannino R J. Cochleates: lipid-based vehicles for gene delivery—concept, achievements and future development. In: Habib N, editor. Cancer gene therapy: past achievements and future challenges. London, England: Plenum Publishing Co.; 2000. pp. 83–94. [DOI] [PubMed] [Google Scholar]
- [46]Zarif L, Segarra L, Jin T, Scolpino A, Hyra D, Perlin D S, Graybill J R, Mannino R J. Oral and systemic delivery of AmB mediated by cochleates. AAPS PharmSci. 1999;1:S-453. [Google Scholar]
Cited by
Sorted by citations
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432 · see citing works
Recent advances in leishmaniasis treatment
Tiuman, T. S., Santos, A. O., Ueda‐Nakamura, T., Filho, B. P. D., & Nakamura, C. V. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.03.021 · Cited by 350 · see citing works
Antifungal drug resistance to azoles and polyenes
Canuto, M. M., & Rodero, F. G. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00371-7 · Cited by 310 · see citing works
Lemke, A., Kiderlen, A. F., & Kayser, O. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1955-9 · Cited by 307 · see citing works
Amphotericin B Formulations and Drug Targeting
Torrado, J. J., Espada, R., Ballesteros, M. P., & Torrado, S. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21179 · Cited by 301 · see citing works
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271 · see citing works
Aspiring Antifungals: Review of Current Antifungal Pipeline Developments
Gintjee, T., Donnelley, M., & Thompson, G. (2020) · Journal of Fungi · doi:10.3390/jof6010028 · Cited by 225 · see citing works
Antifungal drugs: What brings the future?
Daele, R. V., Spriet, I., Wauters, J., Maertens, J. A., Mercier, T., Hecke, S. V., & Brüggemann, R. J. M. (2019) · Medical Mycology · doi:10.1093/mmy/myz012 · Cited by 223 · see citing works
Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy
Faustino, C. M. C., & Pinheiro, L. M. V. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010029 · Cited by 207 · see citing works
Hope on the Horizon: Novel Fungal Treatments in Development
Rauseo, A. M., Coler-Reilly, A. L. G., Larson, L., & Spec, A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa016 · Cited by 199 · see citing works
Antifungal agents: mode of action in yeast cells.
Carrillo‐Muñoz, A. J., Giusiano, G., Ezkurra, P. A., & Quindós, G. (2006) · PubMed · Cited by 191 · see citing works
Formulation of amphotericin B as nanosuspension for oral administration
Kayser, O. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00686-5 · Cited by 187 · see citing works
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 160 · see citing works
The antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149 · see citing works
Italia, J. L., Yahya, M. M., Singh, D., & Kumar, M. N. V. R. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9841-2 · Cited by 144 · see citing works
Bilia, A. R., Piazzini, V., Risaliti, L., Vanti, G., Casamonti, M., Wang, M., & Bergonzi, M. C. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181101110050 · Cited by 143 · see citing works
Advances in Antifungal Drug Development: An Up-To-Date Mini Review
Bouz, G., & Doležal, M. (2021) · Pharmaceuticals · doi:10.3390/ph14121312 · Cited by 130 · see citing works
Recent advances in technologies for vitamin A protection in foods
Loveday, S. M., & Singh, H. (2008) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2008.08.002 · Cited by 127 · see citing works
Optimizing efficacy of amphotericin B through nanomodification
Vyas, S. P., & Gupta, S. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.4.417 · Cited by 117 · see citing works
Treatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111 · see citing works
Serum Differentially Alters the Antifungal Properties of Echinocandin Drugs
Paderu, P., García‐Effrón, G., Balashov, S. V., Delmas, G., Park, S., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01536-06 · Cited by 109 · see citing works
Efficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis
Delmas, G., Park, S., Chen, Z. W., Tan, F., Kashiwazaki, R., Zarif, L., & Perlin, D. S. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2704-2707.2002 · Cited by 110 · see citing works
Advancements and challenges in antifungal therapeutic development
Puumala, E., Fallah, S., Robbins, N., & Cowen, L. E. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00142-23 · Cited by 118 · see citing works
Elongated supramolecular assemblies in drug delivery
Zarif, L. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00010-x · Cited by 101 · see citing works
Self-assembled surfactant nano-structures important in drug delivery: a review.
Sagar, G. H., Arunagirinathan, M. A., & Bellare, J. (2007) · PubMed · Cited by 95 · see citing works
Mucoadhesive chitosan-coated nanostructured lipid carriers for oral delivery of amphotericin B
Tan, S. L. J., Roberts, C. J., & Billa, N. (2018) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2018.1515225 · Cited by 86 · see citing works
Development and research progress of anti-drug resistant fungal drugs
Cui, X., Wang, L., Lü, Y., & Yue, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.004 · Cited by 85 · see citing works
Lipid-based microtubular drug delivery vehicles
Meilander, N. J., Yu, X., Ziats, N. P., & Bellamkonda, R. V. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00214-0 · Cited by 85 · see citing works
Design of amphotericin B oral formulation for antifungal therapy
Liu, M., Chen, M., & Yang, Z. (2017) · Drug Delivery · doi:10.1080/10717544.2016.1225852 · Cited by 85 · see citing works
Cochleates: New Lipid-Based Drug Delivery System
Zarif, L., Graybill, J. R., Perlin, D. S., & Mannino, R. J. (2000) · Journal of Liposome Research · doi:10.3109/08982100009031116 · Cited by 84 · see citing works
Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 85 · see citing works
Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?
Aigner, M., & Lass‐Flörl, C. (2020) · Journal of Fungi · doi:10.3390/jof6020066 · Cited by 79 · see citing works
Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections
Kischkel, B., Rossi, S. A., Santos, S. R. D., Nosanchuk, J. D., Travassos, L. R., & Taborda, C. P. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00463 · Cited by 76 · see citing works
An RNA Transport System in Candida albicans Regulates Hyphal Morphology and Invasive Growth
Elson, S. L., Noble, S. M., Solis, N. V., Filler, S. G., & Johnson, A. D. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000664 · Cited by 76 · see citing works
Novel antifungal agents in clinical trials
Jacobs, S. E., Zagaliotis, P., & Walsh, T. J. (2021) · F1000Research · doi:10.12688/f1000research.28327.1 · Cited by 75 · see citing works
New Approaches for Cryptococcosis Treatment
Spadari, C. D. C., Wirth, F., Lopes, L. B., & Ishida, K. (2020) · Microorganisms · doi:10.3390/microorganisms8040613 · Cited by 73 · see citing works
Optimizing efficacy of Amphotericin B through nanomodification.
BARRATT, G. M., & Bretagne, S. (2007) · PubMed Central · Cited by 72 · see citing works
Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis
Lu, R., Hollingsworth, C., Qiu, J., Wang, A., Hughes, E., Xin, X., Konrath, K. M., Elsegeiny, W., Park, Y.-D., Atakulu, L., et al. (2019) · mBio · doi:10.1128/mbio.00724-19 · Cited by 67 · see citing works
Self-citationWiederhold, N. P. (2022) · Journal of Fungi · doi:10.3390/jof8080857 · Cited by 68 · see citing works
Drug delivery systems against leishmaniasis? Still an open question
Romero, E. L., & Morilla, M. J. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.7.805 · Cited by 65 · see citing works
Drug Delivery by Lipid Cochleates
Zarif, L. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)91018-5 · Cited by 64 · see citing works
Strategies for the design of orally bioavailable antileishmanial treatments
Pham, T.-M.-H., Loiseau, P. M., & BARRATT, G. M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.07.035 · Cited by 61 · see citing works
Intestinal Targeting of Drugs: Rational Design Approaches and Challenges
Filipski, K. J., Varma, M. V. S., El‐Kattan, A. F., Ambler, C. M., Ruggeri, R. B., Goosen, T. C., & Cameron, K. O. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313070002 · Cited by 56 · see citing works
The Effectiveness of Raloxifene-Loaded Liposomes and Cochleates in Breast Cancer Therapy
Ağardan, N. B. M., Değim, Z., Yılmaz, Ş., Altıntaş, L., & Topal, T. (2015) · AAPS PharmSciTech · doi:10.1208/s12249-015-0429-3 · Cited by 55 · see citing works
Potential Strategies to Control the Risk of Antifungal Resistance in Humans: A Comprehensive Review
Rabaan, A. A., Sulaiman, T., Al-Ahmed, S. H., Buhaliqah, Z. A., Buhaliqah, A. A., AlYuosof, B., Alfaresi, M. S., Fares, M. A. A., Alwarthan, S. M., Alkathlan, M. S., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12030608 · Cited by 53 · see citing works
Segarra, I., Movshin, D. A., & Zarif, L. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10173 · Cited by 53 · see citing works
Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments
Lincopán, N., Mamizuka, E. M., & Carmona‐Ribeiro, A. M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki064 · Cited by 52 · see citing works
Chitosan functionalized nanocochleates for enhanced oral absorption of cyclosporine A
Liu, M., Zhong, X., & Yang, Z. (2017) · Scientific Reports · doi:10.1038/srep41322 · Cited by 50 · see citing works
In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments
Lincopán, N. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg383 · Cited by 50 · see citing works
Samaddar, A., & Sharma, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.670731 · Cited by 48 · see citing works
Nanostructured cochleates: a multi-layered platform for cellular transportation of therapeutics
Shende, P. K., Khair, R., & Gaud, R. S. (2019) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1583757 · Cited by 48 · see citing works
Thornton, S. J., & Wasan, K. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902802861 · Cited by 47 · see citing works
Hoenigl, M., Sprute, R., Arastehfar, A. A., Perfect, J. R., Lass‐Flörl, C., Bellmann, R., Prattes, J., Thompson, G. R., Wiederhold, N. P., Al‐Obaidi, M. M., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2086120 · Cited by 46 · see citing works
Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects
Lu, X., Zhou, J., Ming, Y., Wang, Y., He, R., Li, Y., Feng, L., Zeng, B., Du, Y., & Wang, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.013 · Cited by 48 · see citing works
Nanotechnology in Food Systems: A Review
Kiss, É. (2020) · Acta Alimentaria · doi:10.1556/066.2020.49.4.12 · Cited by 44 · see citing works
Novel Antifungal Agents and Their Activity against Aspergillus Species
Vahedi‐Shahandashti, R., & Lass‐Flörl, C. (2020) · Journal of Fungi · doi:10.3390/jof6040213 · Cited by 42 · see citing works
Kayser, O., Olbrich, C., Croft, S. L., & Kiderlen, A. F. (2003) · Parasitology Research · doi:10.1007/s00436-002-0769-2 · Cited by 41 · see citing works
Ling, J. T. S., Roberts, C. J., & Billa, N. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1346-7 · Cited by 38 · see citing works
Oral amphotericin B: The journey from bench to market
Serrano, D. R., & Lalatsa, A. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.04.017 · Cited by 37 · see citing works
Castro, A. L., Nicolas, V., Angelova, A., Mekhloufi, G., Prost, B., Chéron, M., Faivre, V., & BARRATT, G. M. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120688 · Cited by 35 · see citing works
Singh, K., Tiwary, A. K., & Rana, V. (2013) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2013.04.053 · Cited by 35 · see citing works
Nanostructured Self Assembled Lipid Materials for Drug Delivery and Tissue Engineering
Shanmugam, T., & Banerjee, R. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.105 · Cited by 34 · see citing works
In vitro activity of amphotericin B cochleates against Leishmania chagasi
Sesana, A. M., Monti-Rocha, R., Vinhas, S. A., Morais, C. G., Dietze, R., & Lemos, E. M. (2011) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762011000200022 · Cited by 33 · see citing works
Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections
Wasan, E. K., Mandava, T. T., Crespo-Moran, P., Nagy, A., & Wasan, K. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112316 · Cited by 33 · see citing works
Epand, R. F., Mor, A., & Epand, R. M. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0711-9 · Cited by 32 · see citing works
Menez, C., Buyse, M., Besnard, M., Farinotti, R., Loiseau, P. M., & BARRATT, G. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00837-06 · Cited by 32 · see citing works
Delivery strategies for antiparasitics
Kayser, O., & Kiderlen, A. F. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.2.197 · Cited by 32 · see citing works
The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives
de Souza, C. M., Bezerra, B. T., Mellon, D. A., & de Oliveira, H. C. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100341 · Cited by 35 · see citing works
Shanmugam, T., Joshi, N., Ahamad, N., Deshmukh, A., & Banerjee, R. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119482 · Cited by 31 · see citing works
Cochleate drug delivery systems: An approach to their characterization
Castro, A. L., Legrand, F., & BARRATT, G. M. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121225 · Cited by 31 · see citing works
Amphotericin B Formulations – The Possibility of Generic Competition
Serrano, D. R., Ballesteros, M. P., Schätzlein, A. G., Torrado, J. J., & Uchegbu, I. F. (2013) · Pharmaceutical Nanotechnology · doi:10.2174/2211738501999131118125018 · Cited by 31 · see citing works
OAK-based cochleates as a novel approach to overcome multidrug resistance in bacteria
Livne, L., Epand, R. M., Papahadjopoulos‐Sternberg, B., Epand, R. M., & Mor, A. (2010) · The FASEB Journal · doi:10.1096/fj.10-167809 · Cited by 31 · see citing works
The Oral Delivery of Amphotericin B
Torrado, J. J., Serrano, D. R., & Uchegbu, I. F. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.134 · Cited by 31 · see citing works
Batista-Duharte, A., Lastre, M., Romeu, B., Portuondo, D. L., Téllez-Martínez, D., Manente, F. A., Pérez, O., & Carlos, I. Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.09.008 · Cited by 30 · see citing works
Moraru, C. I., Huang, Q., Takhistov, P., Doğan, H., & Kokini, J. L. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374124-0.00021-1 · Cited by 30 · see citing works
Development and characterization of lipidic cochleate containing recombinant factor VIII
Miclea, R. D., Varma, P. R., Peng, A., & Balu‐Iyer, S. V. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.08.001 · Cited by 30 · see citing works
Nanocochleates: A potential drug delivery system
Tilawat, M., & Bonde, S. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.116115 · Cited by 26 · see citing works
Fairuz, S., Nair, R. S., & Billa, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091823 · Cited by 26 · see citing works
Development of antileishmanial lipid nanocomplexes
Pham, T.-M.-H., Gueutin, C., Chéron, M., Abreu, S., Chaminade, P., Loiseau, P. M., & BARRATT, G. M. (2014) · Biochimie · doi:10.1016/j.biochi.2014.06.007 · Cited by 26 · see citing works
Tamargo, B., Monzote, L., Piñón, A., Machín, L., García, M., Scull, R., & Setzer, W. N. (2017) · Medicines · doi:10.3390/medicines4020038 · Cited by 26 · see citing works
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2017) · ASM Press eBooks · doi:10.1128/9781555819583.ch44 · Cited by 26 · see citing works
Current and promising pharmacotherapeutic options for candidiasis
Scorzoni, L., Fuchs, B. B., Junqueira, J. C., & Mylonakis, E. E. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1873951 · Cited by 28 · see citing works
Rolón, M. S., Serrano, D. R., Lalatsa, A., de Pablo, E., Torrado, J. J., Ballesteros, M. P., Healy, A. M., Vega, C., Coronel, C., Bolás-Fernández, F., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01034 · Cited by 25 · see citing works
Efficacy of Cochleated Amphotericin B in Mouse and Human Mucocutaneous Candidiasis
Desai, J. V., Urban, A. K., Swaim, D., Colton, B., Kibathi, L. W., Ferré, E. M. N., Stratton, P., Merideth, M. A., Hunsberger, S., Matkovits, T., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00308-22 · Cited by 24 · see citing works
Dispersion and stabilization of cochleate nanoparticles
Bozó, T., Wacha, A., Mihály, J., Bóta, A., & Kellermayer, M. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.04.030 · Cited by 24 · see citing works
Machín, L., Tamargo, B., Piñón, A., Atíes, R. C., Scull, R., Setzer, W. N., & Monzote, L. (2019) · Molecules · doi:10.3390/molecules24234222 · Cited by 23 · see citing works
Zhong, X., Yang, J., Liu, H., Yang, Z., & Luo, P. (2023) · Drug Delivery · doi:10.1080/10717544.2022.2161671 · Cited by 23 · see citing works
The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies
Zobi, C., & Algül, Ö. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70045 · Cited by 22 · see citing works
Epand, R. F., Sarig, H., Ohana, D., Papahadjopoulos‐Sternberg, B., Mor, A., & Epand, R. M. (2011) · The Journal of Physical Chemistry B · doi:10.1021/jp111242q · Cited by 21 · see citing works
Nanotechnology and Food Safety
Rizvi, S. S. H., Moraru, C. I., Bouwmeester, H., & Kampers, F. W. H. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374845-4.00015-1 · Cited by 20 · see citing works
Cochleate characterization by cryogenic electron microscopy methods: Cryo-TEM and Cryo-SEM
Hollander, A., & Danino, D. (2015) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2015.07.025 · Cited by 20 · see citing works
Antifungal therapy - state of the art at the beginning of the 21st century
Polak, A. (2003) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7974-3_4 · Cited by 19 · see citing works
Nano- and Microdelivery Systems for Marine Bioactive Lipids
Pereira, D. M., Valentão, P., & Andrade, P. B. (2014) · Marine Drugs · doi:10.3390/md12126014 · Cited by 17 · see citing works
Shanmugam, T., Joshi, N., Kaviratna, A., Ahamad, N., Bhatia, E., & Banerjee, R. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01126 · Cited by 16 · see citing works
Castro, A. L., Pomel, S., Cailleau, C., Fournier, N., Dennemont, I., Loiseau, P. M., & BARRATT, G. M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121985 · Cited by 16 · see citing works
McKenzie, B. S., Brady, J. L., & Lew, A. M. (2004) · Immunologic Research · doi:10.1385/ir:30:1:035 · Cited by 16 · see citing works
Innovative therapies for invasive fungal infections in preclinical and clinical development
Yu, Y., Albrecht, K., Gröll, J., & Beilhack, A. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1791819 · Cited by 15 · see citing works
Ibrahim, F., Sivak, O., Wasan, E. K., Bartlett, K. H., & Wasan, K. M. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-158 · Cited by 14 · see citing works
Elson, S. L., Noble, S. M., Solis, N. V., Filler, S. G., & Johnson, A. D. (2009) · PLoS Genetics · doi:10.1371/annotation/17eb3a67-8f49-454b-acbf-5ff2872c27ff · Cited by 15 · see citing works
Feasibility of the preparation of cochleate suspensions from naturally derived phosphatidylserines
Kristensen, S. R., Hassan, K., Andersen, N. S., Steiniger, F., & Kuntsche, J. (2023) · Frontiers in Medical Technology · doi:10.3389/fmedt.2023.1241368 · Cited by 13 · see citing works
- Authors
- Santangelo, R., Paderu, P., Delmas, G., Chen, Z.-W., Mannino, R., Zarif, L., & Perlin, D. S.
- Affiliations
- <!--label omitted: 1-->Public Health Research Institute, New York, New York, 10016,1 and
- <!--label omitted: 2-->BioDelivery Science Inc. UMDNJ, Newark, New Jersey 071032
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-09
- Volume
- 44
- Issue
- 9
- Pages
- 2356-2360
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC90069
- OpenAlex
- W2004315110
- Cited by
- 150
- References
- 44
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 13 · 2021: 13 · 2020: 13 · 2019: 5 · 2018: 3 · 2017: 10 · 2016: 2 · 2015: 3 · 2014: 6 · 2013: 7 · 2012: 4
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service
- National Institute of Allergy and Infectious Diseases (R43AI046040, R43-AI-46040)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- amphotericin B, cochleates, oral drug delivery, systemic candidiasis, Candida albicans, lipid-based drug delivery, antifungal therapy, mouse model
- MeSH terms
- Administration, Oral, Amphotericin B, Animals, Antifungal Agents, Candidiasis, Chemistry, Pharmaceutical, Delayed-Action Preparations, Disease Models, Animal, Drug Carriers, Female, Kidney, Lung, Mice, Inbred BALB C, Drug Delivery Systems, Treatment Outcome, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
